KUALA LUMPUR, March 3 (Bernama) – Known for its ground-breaking technological innovations in clinical trials, Medidata, a Dassault Systèmes company, has exceeded 30,000 clinical trials and nine million study participants.
These milestones, achieved together with more than 2,100 global customers and partners, have been fuelled by Medidata’s platform and life sciences solutions that power smarter treatments and healthier people, while driving greater access to trials.
“This 30,000 trial milestone is a remarkable achievement and a testament to the hard work of so many at Medidata who support trials, develop innovations in AI, and serve our customers while putting patients first.
“We thank the nine million trial participants who chose clinical trials as part of their healthcare journey and the customers who partnered with us to advance human health…and we’re just getting started!” said Medidata Chief Executive Officer, Pascal Daloz in a statement.
Meanwhile, research advocate and Medidata Patient Insights Board Chair, Anne Marie Mercurio said: “As a patient advocate and study participant, I understand the significance of these milestones.
“And beyond the numbers and the data, Medidata’s ongoing commitment to infusing the patient voice into trial designs and solutions, is helping to create a better and more inclusive experience for all participants in clinical studies.”
Medidata has the deepest, widest platform of pioneering programmes including decentralised clinical trials, increasing diversity in clinical studies, and advanced artificial intelligence (AI) solutions for trial design and simulation, site selection, and Synthetic Control Arms.
In addition, Medidata technologies and services are driving more value for customers, helping reach critical development milestones faster, including saving an average of one month in study build time and two months in conducting studies.
Leveraging this volume of trials, patients and data, Medidata delivers unmatched results in the industry with studies conducted in more than 140 countries, and is involved in nearly 40 per cent of company-initiated trial starts globally.
Medidata is a wholly owned subsidiary of Dassault Systèmes, which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalised medicine with the first end-to-end scientific and business platform, from research to commercialisation.
-- BERNAMA
No comments:
Post a Comment